Fluroxan 25 mg/ml (IV Injection or Infusion)

Indications

• Carcinoma of the colon or rectum
• Carcinoma of the stomach and exocrine pancreas
• Carcinoma of the liver
• Carcinoma of the breast
• Carcinoma of the bladder
• Carcinoma of the lung
• Epithelial ovarian carcinoma
• Cervical carcinoma

Pharmacology

• Conversion of fluorouracil into active 5-fluorodeoxyuridine monophosphate (FdUMP)
• Inhibition of thymidylate kinase enzyme
• Formation of stable complex with folate cofactor N-5, 10-methylene tetrahydrofolate
• Incorporation into RNA
• Effect mainly on proliferative phase cells

Dosage & Administration

• Intravenous rapid bolus injection
• Slow infusion with dextrose 5% solution
• Palliative management schedule
• Poor risk patient and inadequate nutritional state schedule
• Maintenance therapy schedules
• Usual adult and pediatric doses
• Intra-arterial infusion
• Combination with radiation and other anticancer drugs

Interaction

• Pre-treatment with cimetidine leading to increased plasma concentrations

Contraindications

• Severely debilitated patients
• Patients with bone marrow suppression
• Pregnant or breastfeeding women
• Patients without malignant illnesses

Side Effects

• Potentially life-threatening effects
• Cardiac effects
• Hematological effects
• Neurological effects
• Allergic reactions
• Decreased bone marrow function
• Hand-foot syndrome
• Severe vomiting and diarrhea
• Temporary hair loss
• Conjunctivitis

Pregnancy & Lactation

• Contraindicated throughout pregnancy
• Risk of teratogenesis in first trimester
• Inhibition of DNA, RNA, and protein synthesis in nursing mothers

Precautions & Warnings

• Highly toxic with narrow margin of safety
• Supervision required for therapeutic response
• Discontinuation signs of toxicity
• Dose limitations for leucopenia, thrombocytopenia, stomatitis, and severe diarrhea

Use in Special Populations

• No dosage recommendations for neonates
• Safety and effectiveness not established in children
• No special precautions for the elderly

Overdose Effects

• No specific antidote
• Treatment consists of supportive care
• Qualitatively similar to side effects

Reconstitution

• Handling by special, trained personnel
• Preparation in designated room
• Prohibition of smoking, eating, and drinking
• Required equipment for handling
• Skin and mucous membrane contact precautions
• Pregnant women warning
• Disposal of contaminated waste by incineration

Storage Conditions

• Store in original carton
• Not exceeding 25℃
• Protect from light

Related Brands

• 5-Fluril 25 mg/ml (IV Injection or Infusion) - techno-drugs-ltd
• Fluracedyl 25 mg/ml (IV Injection or Infusion) - pharmachemie-bv